AGM/EGMJun 29, 2026, 05:32 PM
Theriva Biologics to Increase Authorized Common Stock to 450M Shares
AI Summary
Theriva Biologics, Inc. filed a definitive proxy statement for its 2026 Annual Meeting of Stockholders on August 3, 2026. Key proposals include the election of four directors, ratification of BDO USA, P.C. as auditor, and significant increases in authorized common stock and shares for the stock incentive plan. Stockholders will also vote on the issuance of up to 16.18 million shares upon warrant exercise and a proposal to adjourn the meeting if needed.
Key Highlights
- Annual Meeting of Stockholders scheduled for August 3, 2026.
- Proposes to elect four nominees to the Board of Directors.
- Seeks to ratify BDO USA, P.C. as the independent auditor for 2026.
- Proposes to increase shares for the 2020 Stock Incentive Plan to 6,500,000.
- Proposes to increase authorized common stock to 450,000,000 shares.
- Seeks approval for issuance of up to 16,184,560 shares upon warrant exercise.
- Includes a proposal to adjourn the meeting if needed for proxy solicitation.
Price Impact
More from TOVX